Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 14/20 | 0.40 |
| ▸ | CDK9 | P50750 | 14/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251137 | 0.86 | CNR1 (0.50) | CCNT1CDK9CNR1 | |
| SCHEMBL4065093 | 0.83 | CCNT1 (0.41) | CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL4076052 | 0.83 | CCNT1 (0.41) | CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL4075207 | 0.74 | KCNH2 (0.39) | CCNT1CDK9 | |
| SCHEMBL4064016 | 0.74 | KCNH2 (0.39) | CCNT1CDK9 | |
| SCHEMBL2925641 | 0.72 | GRM2 (0.44) | TDP1 | |
| SCHEMBL2925960 | 0.71 | AKT1 (0.42) | TDP1 | |
| SCHEMBL4069637 | 0.71 | SIRT2 (0.47) | TDP1 | |
| SCHEMBL16135142 | 0.71 | PDK4 (0.58) | — | |
| SCHEMBL1223784 | 0.70 | CYP8B1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605938-B1 | Antibacterial derivatives of napthydrin and quinoline | GLAXO GROUP LTD (GB) | 2009-02-11 | — | — | EP | disclosed |
| EP-1605938-B1 | Antibacterial derivatives of napthydrin and quinoline | GLAXO GROUP LTD (GB) | 2009-02-11 | — | — | EP | disclosed |
| US-20060189601-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189601-A1 | Antibacterial agents | NQO2, NRDC, IFNG | CCNT1 2174/4885CDK9 3122/4885FNTA 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.